- Home
- LPTX vs IMCC Comparison
LPTX vs IMCC Comparison
Compare LPTX & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- IMCC
- Stock Information
- Founded
- LPTX 2011
- IMCC 1980
- Country
- LPTX United States
- IMCC Israel
- Employees
- LPTX N/A
- IMCC N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- IMCC Medicinal Chemicals and Botanical Products
- Sector
- LPTX Health Care
- IMCC Health Care
- Exchange
- LPTX Nasdaq
- IMCC Nasdaq
- Market Cap
- LPTX 11.1M
- IMCC 12.2M
- IPO Year
- LPTX N/A
- IMCC N/A
- Fundamental
- Price
- LPTX $0.31
- IMCC $1.96
- Analyst Decision
- LPTX Hold
- IMCC
- Analyst Count
- LPTX 1
- IMCC 0
- Target Price
- LPTX N/A
- IMCC N/A
- AVG Volume (30 Days)
- LPTX 710.1K
- IMCC 70.6K
- Earning Date
- LPTX 11-12-2025
- IMCC 11-13-2025
- Dividend Yield
- LPTX N/A
- IMCC N/A
- EPS Growth
- LPTX N/A
- IMCC N/A
- EPS
- LPTX N/A
- IMCC N/A
- Revenue
- LPTX N/A
- IMCC $38,430,631.00
- Revenue This Year
- LPTX N/A
- IMCC $47.12
- Revenue Next Year
- LPTX N/A
- IMCC $12.83
- P/E Ratio
- LPTX N/A
- IMCC N/A
- Revenue Growth
- LPTX N/A
- IMCC 5.08
- 52 Week Low
- LPTX $0.22
- IMCC $1.29
- 52 Week High
- LPTX $4.79
- IMCC $7.12
- Technical
- Relative Strength Index (RSI)
- LPTX 53.90
- IMCC 40.62
- Support Level
- LPTX $0.28
- IMCC $1.90
- Resistance Level
- LPTX $0.32
- IMCC $2.14
- Average True Range (ATR)
- LPTX 0.02
- IMCC 0.23
- MACD
- LPTX 0.00
- IMCC 0.01
- Stochastic Oscillator
- LPTX 73.33
- IMCC 42.70
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.